PULSE BIOSCIENCES INC (PLSE) Fundamental Analysis & Valuation

NASDAQ:PLSE • US74587B1017

18.14 USD
-0.44 (-2.37%)
At close: Mar 6, 2026
18.14 USD
0 (0%)
After Hours: 3/6/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PLSE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PLSE. PLSE was compared to 184 industry peers in the Health Care Equipment & Supplies industry. PLSE has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, PLSE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. PLSE Profitability Analysis

1.1 Basic Checks

  • In the past year PLSE has reported negative net income.
  • In the past year PLSE has reported a negative cash flow from operations.
  • In the past 5 years PLSE always reported negative net income.
  • PLSE had a negative operating cash flow in each of the past 5 years.
PLSE Yearly Net Income VS EBIT VS OCF VS FCFPLSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • PLSE has a worse Return On Assets (-76.99%) than 73.91% of its industry peers.
  • Looking at the Return On Equity, with a value of -90.24%, PLSE is in line with its industry, outperforming 40.22% of the companies in the same industry.
Industry RankSector Rank
ROA -76.99%
ROE -90.24%
ROIC N/A
ROA(3y)-62.93%
ROA(5y)-76.25%
ROE(3y)-77.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLSE Yearly ROA, ROE, ROICPLSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K 2K 2.5K

1.3 Margins

  • PLSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLSE Yearly Profit, Operating, Gross MarginsPLSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. PLSE Health Analysis

2.1 Basic Checks

  • PLSE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PLSE has more shares outstanding
  • Compared to 5 years ago, PLSE has more shares outstanding
  • There is no outstanding debt for PLSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PLSE Yearly Shares OutstandingPLSE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
PLSE Yearly Total Debt VS Total AssetsPLSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 45.92 indicates that PLSE is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 45.92, PLSE belongs to the top of the industry, outperforming 98.91% of the companies in the same industry.
  • There is no outstanding debt for PLSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 45.92
ROIC/WACCN/A
WACC10.11%
PLSE Yearly LT Debt VS Equity VS FCFPLSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • PLSE has a Current Ratio of 10.53. This indicates that PLSE is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 10.53, PLSE belongs to the best of the industry, outperforming 93.48% of the companies in the same industry.
  • PLSE has a Quick Ratio of 10.51. This indicates that PLSE is financially healthy and has no problem in meeting its short term obligations.
  • PLSE has a Quick ratio of 10.51. This is amongst the best in the industry. PLSE outperforms 95.65% of its industry peers.
Industry RankSector Rank
Current Ratio 10.53
Quick Ratio 10.51
PLSE Yearly Current Assets VS Current LiabilitesPLSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PLSE Growth Analysis

3.1 Past

  • PLSE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.65%.
  • PLSE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.63% yearly.
EPS 1Y (TTM)-19.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.94%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-20.63%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 19.46% on average over the next years. This is quite good.
  • PLSE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 271.75% yearly.
EPS Next Y-65.75%
EPS Next 2Y-16.3%
EPS Next 3Y3.98%
EPS Next 5Y19.46%
Revenue Next Year1250.2%
Revenue Next 2Y563.33%
Revenue Next 3Y447.37%
Revenue Next 5Y271.75%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PLSE Yearly Revenue VS EstimatesPLSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
PLSE Yearly EPS VS EstimatesPLSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 -2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. PLSE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PLSE. In the last year negative earnings were reported.
  • Also next year PLSE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLSE Price Earnings VS Forward Price EarningsPLSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLSE Per share dataPLSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.3%
EPS Next 3Y3.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PLSE Dividend Analysis

5.1 Amount

  • PLSE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PLSE Fundamentals: All Metrics, Ratios and Statistics

PULSE BIOSCIENCES INC

NASDAQ:PLSE (3/6/2026, 8:00:00 PM)

After market: 18.14 0 (0%)

18.14

-0.44 (-2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-19
Earnings (Next)05-06
Inst Owners8.93%
Inst Owner Change5.47%
Ins Owners72.64%
Ins Owner Change0.38%
Market Cap1.23B
Revenue(TTM)350.00K
Net Income(TTM)-72.78M
Analysts85
Price Target30.6 (68.69%)
Short Float %14.33%
Short Ratio7.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.03%
Min EPS beat(2)8.29%
Max EPS beat(2)17.77%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-39.8%
Min Revenue beat(2)-83.14%
Max Revenue beat(2)3.53%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)36.36%
PT rev (3m)36.36%
EPS NQ rev (1m)14.86%
EPS NQ rev (3m)14.86%
EPS NY rev (1m)9.94%
EPS NY rev (3m)-3.82%
Revenue NQ rev (1m)-50%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)-9.99%
Revenue NY rev (3m)-66.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3512.42
P/FCF N/A
P/OCF N/A
P/B 15.24
P/tB 15.91
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.01
BVpS1.19
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -76.99%
ROE -90.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.93%
ROA(5y)-76.25%
ROE(3y)-77.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.28%
Cap/Sales 95.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.53
Quick Ratio 10.51
Altman-Z 45.92
F-Score4
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)17.31%
Cap/Depr(5y)23.92%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.94%
EPS Next Y-65.75%
EPS Next 2Y-16.3%
EPS Next 3Y3.98%
EPS Next 5Y19.46%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-20.63%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1250.2%
Revenue Next 2Y563.33%
Revenue Next 3Y447.37%
Revenue Next 5Y271.75%
EBIT growth 1Y-36.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.13%
EBIT Next 3Y4.27%
EBIT Next 5Y18.66%
FCF growth 1Y-49.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.92%
OCF growth 3YN/A
OCF growth 5YN/A

PULSE BIOSCIENCES INC / PLSE FAQ

What is the fundamental rating for PLSE stock?

ChartMill assigns a fundamental rating of 3 / 10 to PLSE.


What is the valuation status for PLSE stock?

ChartMill assigns a valuation rating of 0 / 10 to PULSE BIOSCIENCES INC (PLSE). This can be considered as Overvalued.


How profitable is PULSE BIOSCIENCES INC (PLSE) stock?

PULSE BIOSCIENCES INC (PLSE) has a profitability rating of 0 / 10.